Artikel van  Niels van den Donk Over free light chaines

Stem Cell Transplant and the TP53 Deletion in Multiple Myeloma Patients

Een recent overzicht van interventies bij diagnose MGUS, MM etc

For example, patients with high-risk 17p(p53) deletion multiple myeloma can respond to the second-generation IMiD pomalidomide, the second-generation PI carfilzomib, or the combination, and daratumumab achieves responses as a single agent and in combination with IMiDs or PIs in multiply relapsed far advanced disease. As combination-targeted and immune therapies now come into routine clinical practice in multiple myeloma, we will need, in on ongoing fashion, to define which patient subgroups benefit from particular therapies, and conversely, which patients remain high risk and in need of new options. As multiple myeloma is an orphan disease and is itself very heterogeneous, international registries of genomically profiled and clinically annotated patient databases will be necessary to provide the most effective combination therapies to individual patients at distinct time points in their disease course.

Selection of initial chemotherapy for symptomatic multiple myeloma

Prevalence of TP53 Mutations in Del(17p) Myeloma: Spectrum of Mutations and Effect on Survival  (dec-2016 )

Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis  (dec16)

Full Show: Combining Myeloma Vaccines and T Cell Therapies with Stem Cell Transplant with Dr. Muzaffar Qazilbash, MD, MD Anderson Cancer Center